Theratechnologies Announces the Filing of an Application for Registration of Tesamorelin in Israel by Sanofi

Theratechnologies THER today announced that an affiliate of its commercial partner, Sanofi, has filed an application for registration with the Israeli Ministry of Health for tesamorelin. Tesamorelin is an analogue of the growth hormone-releasing factor proposed for the treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy. Currently, there are no approved treatments for lipodystrophy in HIV-infected patients available in Israel. "This marks the first regulatory filing in the Middle East for Theratechnologies' tesamorelin compound, and we are pleased to expand our product's footprint with our partner Sanofi," said John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies. "Sanofi has a global presence and extensive commercialization expertise. We look forward to working with them throughout this regulatory process and in other countries where Sanofi has exclusive commercialization rights for tesamorelin," concluded Mr. Huss. Theratechnologies signed a distribution and licensing agreement with an affiliate of Sanofi on December 6, 2010, granting Sanofi exclusive commercialization rights for tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy in Latin America, Africa and the Middle East.